The beginning of the end for serogroup B meningococcus?

The beginning of the end for serogroup B meningococcus?

Show other versions (1)

Bibliographic Details
Main Authors:	Snape, MD, Pollard, A
Format:	Journal article
Language:	English
Published:	2013

Similar Items

The beginning of the end for serogroup B meningococcus?
by: Snape, MD, et al.
Published: (2013)

Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months.
by: McQuaid, F, et al.
Published: (2015)

Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.
by: Pizza, M, et al.
Published: (2000)

The last of the meningococcus?
by: Segal, S, et al.
Published: (2004)

The price of prevention: what now for immunisation against meningococcus B?
by: Moxon, R, et al.
Published: (2013)

The meningococcus tamed?
by: Pollard, A, et al.
Published: (2002)

The Course of Generalized Meningococcal Infection Caused by Meningococcus Serogroup W135
by: M. V. Ivanova, et al.
Published: (2016-11-01)

Keeping the meningococcus out of the media.
by: Pollard, A, et al.
Published: (1997)

Where next? The emergence of hypervirulent W meningococcus in the Netherlands
by: Snape, M, et al.
Published: (2017)

No conspiracy regarding recommendation for a group B meningococcus vaccine.
by: Pollard, A, et al.
Published: (2014)

The Establishment and Diversification of Epidemic-Associated Serogroup W Meningococcus in the African Meningitis Belt, 1994 to 2012
by: Adam C. Retchless, et al.
Published: (2016-12-01)

Meningococcus, this famous unknown
by: dos Santos Souza, Isabel, et al.
Published: (2021-07-01)

Will booster doses be required for serogroup B meningococcal vaccine?
by: McQuaid, F, et al.
Published: (2014)

No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales - Authors' reply
by: Snape, MD, et al.
Published: (2006)

The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology
by: Vega Masignani, et al.
Published: (2019-04-01)

Serogroup B meningococcal vaccines-an unfinished story.
by: Sadarangani, M, et al.
Published: (2010)

Safety and tolerability of Meningococcus B vaccine in patients with chronical medical conditions (CMC)
by: L. Nicolosi, et al.
Published: (2019-10-01)

A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease.
by: Su, E, et al.
Published: (2011)

Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease.
by: Pollard, A, et al.
Published: (2013)

Demonstration of immunologic memory using serogroup C meningococcal glycoconjugate vaccine.
by: Snape, MD, et al.
Published: (2009)

Towards an improved serogroup B Neisseria meningitidis vaccine.
by: Perrett, K, et al.
Published: (2005)

Inclusion of a dual signal sequence enhances the immunogenicity of a novel viral vectored vaccine against the capsular group B meningococcus
by: Sheerin, D, et al.
Published: (2022)

A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty.
by: Andrews, S, et al.
Published: (2014)

A vaccine against serogroup B Neisseria meningitidis: Dealing with uncertainty
by: Andrews, S, et al.
Published: (2014)

Inclusion of a dual signal sequence enhances the immunogenicity of a novel viral vectored vaccine against the capsular group B meningococcus
by: Dylan Sheerin, et al.
Published: (2022-06-01)

Human protective response induced by meningococcus B vaccine is mediated by the synergy of multiple bactericidal epitopes
by: M. Giuliani, et al.
Published: (2018-02-01)

A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?
by: Martin, N, et al.
Published: (2013)

Challenges and progress in the development of a serogroup B meningococcal vaccine.
by: Lewis, S, et al.
Published: (2009)

Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination.
by: de Whalley, P, et al.
Published: (2013)

Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination
by: De Whalley, P, et al.
Published: (2013)

MENINGOCOCCUS GROWTH STIMULATORS FOR MENINGITIS DIAGNOSTICS BASED ON 2-HYDROXYLALKYLAMINE SALTS
by: A. N. Mirskova, et al.
Published: (2012-09-01)

Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.
by: Snape, MD, et al.
Published: (2010)

TMS--the beginning of the end or the end of the beginning?
by: Ebmeier, K, et al.
Published: (2008)

Exonic single nucleotide polymorphisms within TLR3 associated with infant responses to serogroup C meningococcal conjugate vaccine
by: O'Connor, D, et al.
Published: (2014)

An OMV vaccine derived from a capsular group B meningococcus with constitutive FetA expression: preclinical evaluation of immunogenicity and toxicity
by: Norheim, G, et al.
Published: (2015)

Production of low-avidity antibody by infants after infection with serogroup B meningococci.
by: Pollard, A, et al.
Published: (2000)

Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine.
by: Kelly, D, et al.
Published: (2009)

Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood.
by: Khatami, A, et al.
Published: (2011)

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose.
by: Snape, MD, et al.
Published: (2013)

CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells.
by: Kelly, D, et al.
Published: (2006)